Pharmaceuticals

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

bexib
By bexib 0 Min Read

In this interview, Melissa Krebs, CEO and Founder of GelSana, discusses the journey of developing a cutting-edge biomaterial that has the potential to transform the $78 billion wound care market.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

Share This Article
Previous Article Calculated Risk: Update: Lumber prices unchanged year-over-year
Next Article Efficient and Inefficient – Econlib
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Big Digital Tech Moves Into Synthetic Biology: The Generative AI Rush / Black Box Biotech P1/2
Economy
AI accounted for 31% of VC funding in Q3
Banking
Prime Minister Netanyahu goes even further, announces intention to turn Lebanon into Gaza, refuses to inform US about plans to attack Iran (updated)
Economy
Railway vehicle loading in September decreased compared to the previous year, but intermodal increased
Economy